12:07 PM EDT, 08/21/2024 (MT Newswires) -- Cosmos Health ( COSM ) said Wednesday its Cana Laboratories unit has completed the latest upgrades to its manufacturing capabilities and secured a contract manufacturing deal with Provident Pharmaceuticals for 4.32 million units of the DE3-SOLE vial.

Separately, Cosmos Health ( COSM ) said that under its deal with Virax Biolabs ( VRAX ) , it continues to hold the distribution rights for the mpox virus real-time PCR detection kits.

The company has exclusive distribution rights in Greece and Cyprus, and nonexclusive rights across Europe, it said.

Cosmos Health ( COSM ) shares were up nearly 21% in recent trading, while Virax rose 66%.

Price: 1.29, Change: +0.22, Percent Change: +20.56